Literature DB >> 9828237

Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients.

C García-Monzón1, P Jara, M Fernández-Bermejo, L Hierro, E Frauca, C Camarena, C Díaz, A De la Vega, J Larrauri, C García-Iglesias, M J Borque, P Sanz, L García-Buey, J A Moreno-Monteagudo, R Moreno-Otero.   

Abstract

Limited information is available regarding the characteristics of the hepatitis C virus (HCV) infection in children. We compared the epidemiological background along with the virological and histological features as well as the intrahepatic immunologic phenotype of both children and adults with chronic hepatitis C (CHC). Serum samples of 24 pediatric and 32 adult patients were drawn for alanine transaminase (ALT) levels, HCV-typing, and viral load. The histological diagnosis and a semiquantitative immunohistochemical assessment were performed in all patients. The majority of children (62%) had been transfused and the mean duration of viral infection in these cases was 11 +/- 4 years, being similar in adults (11 +/- 9 years, not significant). Although genotype distribution was similar, viral load was lower in children than in adults. The mildest histological forms of chronic hepatitis along with a weak intrahepatic immunological phenotype were significantly more frequent among children than adult patients. In conclusion, in children with CHC, perinatal blood transfusion was the most frequent source of viral infection and the liver disease was characterized by both low ALT level and viral load, as well as the mildest histological and immunohistochemical forms of chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828237     DOI: 10.1002/hep.510280633

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Active surveillance of hepatitis C infection in the UK and Ireland.

Authors:  D M Gibb; P E Neave; P A Tookey; M Ramsay; H Harris; K Balogun; D Goldberg; G Mieli-Vergani; D Kelly
Journal:  Arch Dis Child       Date:  2000-04       Impact factor: 3.791

2.  Clinical spectrum and histopathologic features of chronic hepatitis C infection in children.

Authors:  Parvathi Mohan; Camilla Colvin; Chevelle Glymph; Roma R Chandra; David E Kleiner; Kantilal M Patel; Naomi L C Luban; Harvey J Alter
Journal:  J Pediatr       Date:  2007-02       Impact factor: 4.406

3.  Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients.

Authors:  Wendy A Henderson; Ravi Shankar; Jordan J Feld; Colleen M Hadigan
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

4.  CD4+ and CD8+ T Cell Activation in Children with Hepatitis C.

Authors:  Melissa A Sheiko; Lucy Golden-Mason; Silvia Giugliano; Christine Waasdorp Hurtado; Cara L Mack; Michael R Narkewicz; Hugo R Rosen
Journal:  J Pediatr       Date:  2015-12-30       Impact factor: 4.406

5.  Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1.

Authors:  Sophie Canobio; Cynthia M Guilbert; Myriam Troesch; Johanne Samson; Mireille Lemay; Veronique Anne Pelletier; Anne-Claude Bernard-Bonnin; Rafal Kozielski; Normand Lapointe; Steven R Martin; Hugo Soudeyns
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

6.  Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.

Authors:  Daniel H Leung; Stefan Wirth; Betty B Yao; Rolando M Viani; Regino P Gonzalez-Peralta; Maureen M Jonas; Steven J Lobritto; Michael R Narkewicz; Etienne Sokal; Clàudia Fortuny; Evelyn K Hsu; Antonio Del Valle-Segarra; Jiuhong Zha; Lois Larsen; Li Liu; Diana L Shuster; Daniel E Cohen; Philip Rosenthal
Journal:  Hepatol Commun       Date:  2018-10-05

7.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.